Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Ferrero

Showing results (441-450 of 482) with videos related to

Pageof 49
Sort By:
Hemasphere|November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 21, 2023
Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: Perioperative and long-term results from a propensity-score based studyGiorgio Bogani, Violante Di Donato, Andrea Papadia, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
British Journal of Haematology|April 29, 2025
Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national databaseMaddalena Casale, Raffaella Colombatti, Manuela Balocco, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
Leukemia & Lymphoma|January 29, 2026
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in ItalyDaniela Estefania Banegas, Isacco Ferrarini, Andrea Bernardelli, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Cancers|January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III TrialGian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
Leukemia|November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Pageof 49

Showing results (441-450 of 482) with videos related to

Sort By:
Pageof 49
Hemasphere|November 17, 2025
Real-life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy-cell leukemia: A multicenter Italian retrospective study (HCL-PG03R)Luca De Carolis, Monia Capponi, Andrea Bernardelli, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 21, 2023
Hysterectomy alone vs. hysterectomy plus sentinel node mapping in endometrial cancer: Perioperative and long-term results from a propensity-score based studyGiorgio Bogani, Violante Di Donato, Andrea Papadia, et al.
Haematologica|April 1, 2025
<i>Erratum</i> to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
British Journal of Haematology|April 29, 2025
Underlying disease is the main risk factor in post-splenectomy complication risk: Data from a national databaseMaddalena Casale, Raffaella Colombatti, Manuela Balocco, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
Leukemia & Lymphoma|January 29, 2026
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in ItalyDaniela Estefania Banegas, Isacco Ferrarini, Andrea Bernardelli, et al.
The Lancet. Haematology|December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trialMarco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Cancers|January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III TrialGian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
Blood Advances|January 14, 2025
Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trialSimone Ragaini, Anna Galli, Elisa Genuardi, et al.
Leukemia|November 7, 2025
The integration of gene mutations and copy number variations refines the prognosis of mantle cell lymphoma: long-term results of the Fondazione Italiana Linfomi MCL0208 clinical trialRiccardo Moia, Simone Ragaini, Luciano Cascione, et al.
Pageof 49